Who is sponsoring NCT01391559?

NCT01391559 is sponsored by Dartmouth-Hitchcock Medical Center.

What condition does NCT01391559 study?

NCT01391559 studies Chronic Obstructive Pulmonary Disease.

What drugs are being tested in NCT01391559?

Interventions: arformoterol, salmeterol.

What is the status of NCT01391559?

NCT01391559 is currently COMPLETED.

Last reviewed 2013-07-05 · How we verify

Efficacy of Inhaling Bronchodilator Medications in Patients With Chronic Obstructive Pulmonary Disease Who Have a Low Peak Inspiratory Flow Rate

NCT01391559 NA COMPLETED Results posted

Some patients with Chronic Obstructive Pulmonary Disease (COPD) report that they are uncertain whether they achieve clinical benefit using a dry-powder inhaler (DPI). One possible explanation is that the patient is unable to inhale the dry powder bronchodilator medication into the lower respiratory tract due to a low peak inspiratory flow rate (PIFR). A PIFR \< 60 l/min is considered to be suboptimal flow for a DPI, including the Diskus device. The hypothesis of the study is that the forced expiratory volume in 1 second (FEV1) measured at two hours after inhalation of the study medication will be higher with arformoterol solution (15 mcg) from a nebulizer compared with salmeterol dry powder (50 mcg) inhaled from the Diskus.

Details

Lead sponsor	Dartmouth-Hitchcock Medical Center
Phase	NA
Status	COMPLETED
Enrolment	20
Start date	2011-07
Completion	2012-10

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

arformoterol
salmeterol

Primary outcomes

Change in Forced Expiratory Volume in 1 Second (FEV1) From Baseline at Two Hours After Inhalation of the Study Medication — 2 hours
FEV1

Countries

United States